Cargando…
Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report
Tumoral cavity formation is a characteristic phenomenon reported in anti-angiogenic therapy in lung lesions. A 57-year-old male with multiple pulmonary metastases from colorectal cancer treated with an oral tyrosine kinase inhibitor, regorafenib, exhibited a characteristic cavity formation after the...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727027/ https://www.ncbi.nlm.nih.gov/pubmed/26870193 http://dx.doi.org/10.3892/ol.2015.3905 |
_version_ | 1782411916261457920 |
---|---|
author | KAWASAKI, KENTA HAMAMOTO, YASUO ADACHI, MASAYUKI KANAI, TAKANORI TAKAISHI, HIROMASA |
author_facet | KAWASAKI, KENTA HAMAMOTO, YASUO ADACHI, MASAYUKI KANAI, TAKANORI TAKAISHI, HIROMASA |
author_sort | KAWASAKI, KENTA |
collection | PubMed |
description | Tumoral cavity formation is a characteristic phenomenon reported in anti-angiogenic therapy in lung lesions. A 57-year-old male with multiple pulmonary metastases from colorectal cancer treated with an oral tyrosine kinase inhibitor, regorafenib, exhibited a characteristic cavity formation after the first two cycles. The decrease in the size of tumors was calculated as 38%, and there were associated decreases in the serum concentrations of the tumor markers carcinoembryonic antigen and CA19-9. After eight cycles of treatment, the cavity gradually disappeared through filling-in. This unique morphological response is not only reported in lung cancer but also in liver metastasis in colorectal cancer. However, the association between morphological changes including cavity formation and clinical benefit remains controversial. Pulmonary hemorrhage and pneumothorax are well-known consequences of cavitation, as reported with the other anti-angiogenic inhibitors. Early tumor cavitation in lung metastasis may demonstrate the predictive potential of regorafenib in colorectal cancer, although it is necessary to be mindful of toxicity. |
format | Online Article Text |
id | pubmed-4727027 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-47270272016-02-11 Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report KAWASAKI, KENTA HAMAMOTO, YASUO ADACHI, MASAYUKI KANAI, TAKANORI TAKAISHI, HIROMASA Oncol Lett Articles Tumoral cavity formation is a characteristic phenomenon reported in anti-angiogenic therapy in lung lesions. A 57-year-old male with multiple pulmonary metastases from colorectal cancer treated with an oral tyrosine kinase inhibitor, regorafenib, exhibited a characteristic cavity formation after the first two cycles. The decrease in the size of tumors was calculated as 38%, and there were associated decreases in the serum concentrations of the tumor markers carcinoembryonic antigen and CA19-9. After eight cycles of treatment, the cavity gradually disappeared through filling-in. This unique morphological response is not only reported in lung cancer but also in liver metastasis in colorectal cancer. However, the association between morphological changes including cavity formation and clinical benefit remains controversial. Pulmonary hemorrhage and pneumothorax are well-known consequences of cavitation, as reported with the other anti-angiogenic inhibitors. Early tumor cavitation in lung metastasis may demonstrate the predictive potential of regorafenib in colorectal cancer, although it is necessary to be mindful of toxicity. D.A. Spandidos 2016-01 2015-11-10 /pmc/articles/PMC4727027/ /pubmed/26870193 http://dx.doi.org/10.3892/ol.2015.3905 Text en Copyright: © Kawasaki et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles KAWASAKI, KENTA HAMAMOTO, YASUO ADACHI, MASAYUKI KANAI, TAKANORI TAKAISHI, HIROMASA Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report |
title | Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report |
title_full | Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report |
title_fullStr | Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report |
title_full_unstemmed | Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report |
title_short | Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report |
title_sort | early tumor cavitation with regorafenib in metastatic colorectal cancer: a case report |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727027/ https://www.ncbi.nlm.nih.gov/pubmed/26870193 http://dx.doi.org/10.3892/ol.2015.3905 |
work_keys_str_mv | AT kawasakikenta earlytumorcavitationwithregorafenibinmetastaticcolorectalcanceracasereport AT hamamotoyasuo earlytumorcavitationwithregorafenibinmetastaticcolorectalcanceracasereport AT adachimasayuki earlytumorcavitationwithregorafenibinmetastaticcolorectalcanceracasereport AT kanaitakanori earlytumorcavitationwithregorafenibinmetastaticcolorectalcanceracasereport AT takaishihiromasa earlytumorcavitationwithregorafenibinmetastaticcolorectalcanceracasereport |